STARPharmaceuticals
Strides Pharma Science Ltd — Balance Sheet
₹937.75
+1.19%
Strides Pharma Science Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Ordinary Shares Number | 9.22 Cr | 9.19 Cr | 9.03 Cr | 8.98 Cr | — |
| Share Issued | 9.22 Cr | 9.19 Cr | 9.03 Cr | 8.98 Cr | — |
| Net Debt | 1.68K Cr | 2.25K Cr | 2.47K Cr | 2.62K Cr | — |
| Total Debt | 1.88K Cr | 2.52K Cr | 3.03K Cr | 3.03K Cr | — |
| Tangible Book Value | 1.44K Cr | 1.07K Cr | 1.14K Cr | 1.25K Cr | — |
| Invested Capital | 4.35K Cr | 4.54K Cr | 4.99K Cr | 5.15K Cr | — |
| Working Capital | 510.16 Cr | 93.23 Cr | 255.74 Cr | -47.27 Cr | — |
| Net Tangible Assets | 1.44K Cr | 1.07K Cr | 1.14K Cr | 1.25K Cr | — |
| Capital Lease Obligations | 84.02 Cr | 102.34 Cr | 255.11 Cr | 233.06 Cr | — |
| Common Stock Equity | 2.55K Cr | 2.13K Cr | 2.21K Cr | 2.36K Cr | — |
| Total Capitalization | 3.12K Cr | 2.80K Cr | 3.35K Cr | 3.19K Cr | — |
| Total Equity Gross Minority Interest | 2.59K Cr | 2.07K Cr | 2.17K Cr | 2.38K Cr | — |
| Minority Interest | 34.63 Cr | -53.86 Cr | -39.38 Cr | 24.09 Cr | — |
| Stockholders Equity | 2.55K Cr | 2.13K Cr | 2.21K Cr | 2.36K Cr | — |
| Other Equity Interest | 0.51 Cr | 3.09 Cr | 19.42 Cr | 2.45 Cr | — |
| Retained Earnings | 458.92 Cr | -284.49 Cr | -200.33 Cr | 2.31 Cr | — |
| Additional Paid In Capital | 1.57K Cr | 1.88K Cr | 1.81K Cr | 1.79K Cr | — |
| Capital Stock | 92.16 Cr | 91.90 Cr | 90.30 Cr | 89.79 Cr | — |
| Common Stock | 92.16 Cr | 91.90 Cr | 90.30 Cr | 89.79 Cr | — |
| Total Liabilities Net Minority Interest | 3.46K Cr | 3.77K Cr | 4.47K Cr | 4.59K Cr | — |
| Total Non Current Liabilities Net Minority Interest | 870.74 Cr | 888.79 Cr | 1.48K Cr | 1.18K Cr | — |
| Derivative Product Liabilities | 9.98 Cr | 9.13 Cr | 7.48 Cr | 25.10 Cr | — |
| Tradeand Other Payables Non Current | 4.05 Cr | 3.83 Cr | 3.37 Cr | 29.18 Cr | — |
| Non Current Deferred Taxes Liabilities | 119.36 Cr | 40.34 Cr | 44.57 Cr | 35.72 Cr | — |
| Long Term Debt And Capital Lease Obligation | 622.70 Cr | 743.13 Cr | 1.34K Cr | 1.02K Cr | — |
| Long Term Capital Lease Obligation | 51.46 Cr | 71.64 Cr | 203.67 Cr | 186.47 Cr | — |
| Long Term Debt | 571.24 Cr | 671.50 Cr | 1.14K Cr | 835.62 Cr | — |
| Long Term Provisions | 113.94 Cr | 91.63 Cr | 75.25 Cr | 65.88 Cr | — |
| Current Liabilities | 2.59K Cr | 2.88K Cr | 2.99K Cr | 3.41K Cr | — |
| Other Current Liabilities | 80.08 Cr | 68.92 Cr | 76.48 Cr | 3.04 Cr | — |
| Current Deferred Taxes Liabilities | 34.04 Cr | 40.42 Cr | 26.71 Cr | 23.81 Cr | — |
| Current Debt And Capital Lease Obligation | 1.26K Cr | 1.77K Cr | 1.69K Cr | 2.00K Cr | — |
| Current Capital Lease Obligation | 32.56 Cr | 30.70 Cr | 51.44 Cr | 46.60 Cr | — |
| Current Debt | 1.22K Cr | 1.74K Cr | 1.63K Cr | 1.96K Cr | — |
| Current Provisions | 81.21 Cr | 71.53 Cr | 122.49 Cr | 122.62 Cr | — |
| Payables | 1.19K Cr | 967.55 Cr | 1.12K Cr | 1.22K Cr | — |
| Other Payable | 151.89 Cr | 115.14 Cr | 133.58 Cr | 151.84 Cr | — |
| Dividends Payable | 0.69 Cr | 0.82 Cr | 0.97 Cr | 1.09 Cr | — |
| Total Tax Payable | 34.04 Cr | 40.42 Cr | 26.71 Cr | 23.81 Cr | — |
| Accounts Payable | 1.03K Cr | 851.59 Cr | 982.34 Cr | 1.07K Cr | — |
| Total Assets | 6.05K Cr | 5.84K Cr | 6.64K Cr | 6.98K Cr | — |
| Total Non Current Assets | 2.95K Cr | 2.87K Cr | 3.39K Cr | 3.61K Cr | — |
| Other Non Current Assets | 44.32 Cr | 24.25 Cr | 26.53 Cr | 10.48 Cr | — |
| Non Current Prepaid Assets | 77.51 Cr | 72.30 Cr | 37.86 Cr | 41.32 Cr | — |
| Prepaid Assets | 189.97 Cr | 236.42 Cr | 212.06 Cr | 197.43 Cr | — |
| Non Current Deferred Taxes Assets | 269.13 Cr | 267.35 Cr | 265.03 Cr | 215.15 Cr | — |
| Financial Assets | 2.51 Cr | 1.47 Cr | 0.00 | — | — |
| Investmentin Financial Assets | 339.49 Cr | 12.21 Cr | 56.24 Cr | 6.07 Cr | — |
| Available For Sale Securities | 332.97 Cr | 5.69 Cr | 56.24 Cr | 6.07 Cr | — |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | 6.52 Cr | 6.52 Cr | 0.00 | — | — |
| Long Term Equity Investment | 10.68 Cr | 189.30 Cr | 385.92 Cr | 535.55 Cr | — |
| Investmentsin Joint Venturesat Cost | 0.71 Cr | 1.27 Cr | 8.23 Cr | 8.20 Cr | — |
| Investmentsin Associatesat Cost | 9.97 Cr | 188.03 Cr | 377.68 Cr | 527.35 Cr | — |
| Investment Properties | 11.17 Cr | 11.90 Cr | 12.58 Cr | 13.17 Cr | — |
| Goodwill And Other Intangible Assets | 1.11K Cr | 1.06K Cr | 1.08K Cr | 1.11K Cr | — |
| Other Intangible Assets | 567.97 Cr | 527.12 Cr | 563.09 Cr | 624.98 Cr | — |
| Goodwill | 546.57 Cr | 529.41 Cr | 513.76 Cr | 485.91 Cr | — |
| Net PPE | 1.02K Cr | 977.30 Cr | 1.39K Cr | 1.52K Cr | — |
| Accumulated Depreciation | -709.04 Cr | -659.74 Cr | -721.79 Cr | -646.25 Cr | — |
| Gross PPE | 1.73K Cr | 1.64K Cr | 2.11K Cr | 2.16K Cr | — |
| Construction In Progress | 137.74 Cr | 98.63 Cr | 67.75 Cr | 58.81 Cr | — |
| Other Properties | 880.69 Cr | 878.67 Cr | 1.32K Cr | 1.46K Cr | — |
| Machinery Furniture Equipment | 947.48 Cr | 913.59 Cr | 1.26K Cr | 1.31K Cr | — |
| Buildings And Improvements | 499.37 Cr | 483.21 Cr | 642.43 Cr | 652.41 Cr | — |
| Land And Improvements | 142.89 Cr | 141.61 Cr | 140.97 Cr | 138.28 Cr | — |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Assets | 3.10K Cr | 2.97K Cr | 3.25K Cr | 3.36K Cr | — |
| Other Current Assets | 227.37 Cr | 271.72 Cr | 222.98 Cr | 197.03 Cr | — |
| Hedging Assets Current | 8.40 Cr | 4.67 Cr | 3.64 Cr | 0.91 Cr | — |
| Restricted Cash | 7.66 Cr | 7.37 Cr | 6.10 Cr | 3.17 Cr | — |
| Inventory | 1.28K Cr | 1.13K Cr | 1.15K Cr | 1.17K Cr | — |
| Finished Goods | 749.49 Cr | 537.71 Cr | 547.06 Cr | 527.26 Cr | — |
| Work In Process | 52.09 Cr | 47.93 Cr | 51.04 Cr | 48.19 Cr | — |
| Raw Materials | 475.99 Cr | 540.61 Cr | 548.41 Cr | 598.35 Cr | — |
| Other Receivables | 216.52 Cr | 161.28 Cr | 109.41 Cr | 597.63 Cr | — |
| Taxes Receivable | 0.00 | 5.08 Cr | 0.00 | — | — |
| Accounts Receivable | 1.20K Cr | 1.14K Cr | 1.30K Cr | 1.21K Cr | — |
| Allowance For Doubtful Accounts Receivable | -41.42 Cr | -50.04 Cr | -45.23 Cr | -42.22 Cr | — |
| Gross Accounts Receivable | 1.24K Cr | 1.19K Cr | 1.34K Cr | 1.25K Cr | — |
| Cash Cash Equivalents And Short Term Investments | 198.62 Cr | 289.56 Cr | 360.70 Cr | 184.19 Cr | — |
| Other Short Term Investments | 86.06 Cr | 128.54 Cr | 57.20 Cr | 13.46 Cr | — |
| Cash And Cash Equivalents | 112.56 Cr | 161.02 Cr | 303.50 Cr | 170.73 Cr | — |
| Cash Equivalents | 4.85 Cr | 72.72 Cr | 190.96 Cr | 1.46 Cr | — |
| Cash Financial | 107.71 Cr | 88.30 Cr | 112.54 Cr | 169.27 Cr | — |
| Assets Held For Sale Current | — | 0.00 | 108.11 Cr | 0.00 | 0.00 |
| Other Non Current Liabilities | — | — | 1.83 Cr | 1.60 Cr | 0.11 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Strides Pharma Science Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.